Clave Capital

A venture capital firm specializing in early-stage investments in innovative companies across various sectors in Spain. With over 20 years of experience, Clave Capital has made more than 90 investments, focusing on sectors such as technology, healthcare, energy, agri-food, and biotech. The firm manages approximately €90 million and is launching a new €80 million fund targeting health innovation projects, including eHealth, medtech, nutrition, and biotech. Clave Capital emphasizes close collaboration with founders, management teams, and the innovation ecosystem to support company growth and address emerging market challenges. Their strategy combines financial investment with strategic support, aiming to generate sustainable value for both investors and companies. This approach fosters competitiveness, knowledge transfer, and positive territorial impact, integrating innovation, economic development, and social responsibility. Clave Capital's commitment to technology transfer is evident in their recent exit from Abanzamed, achieving an equity multiple of 4.25x for their fund UN I+D+i Technology Transfer F.C.R., launched in 2016 in collaboration with the University of Navarra. This divestment reflects Clave Capital's dedication to supporting technology transfer projects and generating value from the initial phase through to exit. Their track record includes investments in over 65 companies, demonstrating their expertise in identifying and nurturing innovative ventures across diverse sectors. Clave Capital's longevity in the investment space speaks to their adaptability and consistent performance, having successfully navigated multiple economic cycles while maintaining their commitment to fostering innovation and supporting entrepreneurial talent across their target sectors.